reports
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
DLTR DOLLAR TREE INC.
CVGW CALAVO GROWERS INC.
CAR AVIS BUDGET GROUP INC.
A AGILENT TECHNOLOGIES INC.
MSB MESABI TRUST
PESI PERMA-FIX ENVIRONMENTAL SERVICES INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
TATT TAT TECHNOLOGIES LTD.
IIIN INSTEEL INDUSTRIES INC.
SJT SAN JUAN BASIN ROYALTY TRUST
CHCI COMSTOCK HOLDING COMPANIES
SEZI SENZIME AB
ANAB ANAPTYSBIO INC.
TIGO MILLICOM INTERNATIONAL CELLULAR S.A.
FRAF FRANKLIN FINANCIAL SERVICES CO.
OVBC OHIO VALLEY BANC CORP
NEON NEONODE INC.
SMMT SUMMIT THERAPEUTICS INC
HTZ HERTZ GLOBAL HLDGS INC
MPTI M TRON INDUSTRIES INC
NUTX NUTEX HEALTH INC
ZBIO PROSHARES ULTRAPRO SHORT NASDAQ BIOTECHNOLOGY
VRM VROOM INC
Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...
CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...
Agilent Research Catalyst Award Presented to Columbia University for P...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...
Agilent Technologies Inc: 1 director
A director at Agilent Technologies Inc sold 6,971 shares at 126.382USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Agilent to Participate in TD Cowen Health Care Conference
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference at 9:50-10:20 a.m. Eastern on Tuesday, March 4, 2025, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available on the . About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring gr...
Agilent Reports First-Quarter Fiscal Year 2025 Financial Results
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% core(1) compared to the first quarter of 2024. First-quarter GAAP net income was $318 million, or $1.11 per share. This compares with $348 million, or $1.18 per share, in the first quarter of fiscal year 2024. Non-GAAP(2) net income was $377 million, or $1.31 per share during the quarter, compared with $380 million or $1.29 per share during the year-ago quarter. “The Agilent team delive...
Agilent Announces Cash Dividend of 24.8 Cents per Share
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on April 23, 2025, to all shareholders of record as of the close of business on April 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent’s board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers b...
Agilent to Announce First-Quarter Fiscal Year 2025 Financial Results o...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2025 after the stock market closes on Wednesday, Feb. 26. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST. To join the listen-only conference call webcast, click the link on the of Agilent’s investor relations website. A recording of the call also will be available on the website for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical la...
Agilent Automated Workflows at SLAS2025: Connecting with Confidence
SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) announced today that it will feature new automated laboratory workflow solutions at the being held January 25-29, at the San Diego Convention Center in California. Agilent is a leader in advancing automation solutions to help customers optimize lab performance, efficiency, and reproducibility across their entire pipeline, from research and drug discovery to development and manufacturing processes. Automation is becoming increasingly critical for labs as they navigate the competitive landscape. Agilent's automation solutions include sample an...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 16 January 2025 in which we reassessed the appropriateness of the ratings in the...
Agilent Presents Solutions Innovation Research Awards to Aarhus Univer...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced Solutions Innovation Research Awards (SIRA) have been presented to Professor Anders Bentien of , Professor Walter Gössler of , and Professor Gregory Offer of . These separate awards recognize their outstanding contributions to battery research. Developing new materials for more efficient and durable batteries is essential to reducing fossil fuel reliance and meeting global energy storage needs. Given the limited supply of critical metals like lithium, it is crucial to focus on pioneering new materials and recovering and reusin...
Agilent to Present at the 43rd Annual J.P. Morgan Healthcare Conferenc...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Bob McMahon will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 14, 2025, at 9:45 a.m. Pacific time. A live audio webcast and replay of the presentation will be available on the . About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full ran...
Agilent Companion Diagnostic Assay PD-L1 IHC 28-8 pharmDx Receives Eur...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for (Code SK005). This CDx assay has previously been CE-IVD–marked for sales in the European Union and is now certified in accordance with the new EU Regulation for in vitro diagnostic medical devices (IVDR) 1. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Agilent’s PD-L1 IHC 28-8 pharmDx (Code SK005) provides clinically relevant information about PD-L1 expression – a critical biomarke...
Agilent Reports Fourth-Quarter Fiscal Year 2024 Financial Results
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.70 billion for the fourth quarter ended October 31, 2024, an increase of 0.8% reported and a decline of 0.3% core(1) compared to the fourth quarter of 2023. Fourth-quarter GAAP net income was $351 million, or $1.22 per share. This compares with $475 million, or $1.62 per share, in the fourth quarter of fiscal year 2023. Non-GAAP(2) net income was $418 million, or $1.46 per share during the quarter, compared with $404 million or $1.38 per share during the fourth quarter a year ago. “The A...
Agilent Announces New Organizational Structure to Support its Market-F...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced a new organizational structure to accelerate the company’s operational transformation to drive higher growth through a market-focused, customer-centric enterprise strategy. The new structure, including new leadership roles, takes effect immediately. “This is an important step in our transformation to become a nimbler company that puts our customers and our markets first,” said Agilent President and CEO Padraig McDonnell. “It builds on Agilent’s legacy of success and evolves our business to further stre...
Agilent Increases Cash Dividend to 24.8 Cents per Share
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies, Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 24.8 cents per share of common stock, a 5% increase over the previous dividend. The quarterly dividend will be paid on Jan. 22, 2025, to all shareholders of record as of the close of business on Dec. 31, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent’s board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory te...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.